Medtronic’s stent is intended to provide an off-the-shelf endovascular solution for treating thoracoabdominal aortic aneurysm. Credit: Medtronic plc.

Medical device producer Medtronic has secured Breakthrough Device designation from the US Food and Drug Administration (FDA) for its implantable Left Ventricular Assist Device (LVAD) for patients suffering from advanced heart failure.

LVAD systems include an implanted heart pump to raise the amount of blood circulating the body.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The pump is linked to a driveline cable, extending outside the body to a controller, then connected to power sources (AC or DC adapter, batteries).

The future system is designed to be fully implanted within the body.

The FDA Breakthrough Device Programme is designed to help patients receive access to breakthrough technologies that come with the potential to offer more effective treatment or diagnosis for life-threatening or debilitating diseases.

Under the programme, the FDA will offer Medtronic with priority review and interactive communication concerning device development and clinical trial protocols, through to commercialisation decisions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Medtronic Fully Implantable LVAD is currently in early stage research and development and is not available for sale anywhere in the world.

Medtronic provides a range of medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

Earlier this month, the US FDA granted breakthrough device designation to Medtronic’s minimally invasive Valiant TAAA Stent Graft System.

Valiant TAAA Stent Graft System is designed to repair a thoracoabdominal aortic aneurysm (TAAA). A TAAA causes swelling of the aorta, extending from the chest into the abdomen.

Commonly, TAAA impacts the branch arteries supplying blood to several internal organs. The condition accounts for approximately 15% of all thoracic aneurysms.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact